Company Introduction

Established in Dec 2016, Ever Supreme Bio Technology (Ever Supreme) targets the cell therapy market for unmet medical needs. Through obtaining exclusive technology licenses from Academia Sinica, National Chiao Tung University and China Medical University (Taiwan), Ever Supreme conducts R&D of immune cell therapy and stem cell drugs, and develops the cell therapy for critical illnesses, providing new hopes for critical illness treatment along with personalized cell therapy in response to individual differences.

Brief description of main products or services 

Ever Supreme focuses on two major businesses described as below:
 
(1) New drug development:
 
Ever Supreme focuses on the immune cell therapy treating cancers and stem cell therapy treating critical illnesses, including acute myocardial infarction, acute ischemic stroke, and COVID-19.
 
(2) Cell preparation CMO regulated by the Regulations Governing Specific Cellular Therapeutic Technology:
 
The Ministry of Health and Welfare (MOHW) announced the amended Regulations Governing Specific Cellular Therapeutic Technology (RGSCTT) in Sep 2018. The RGSCTT allows the use of six cell therapy technologies. Ever Supreme has cell preparation sites meeting the requirements of Good Tissue Practices (GTP), and can partner up with domestic medical institutions to provide cell preparations approved by RGSCTT. Hence, Ever Supreme can apply the immune cell and stem cell therapy technologies under the new drug development stage to end markets in advance, making Ever Supreme one of the few new drug developers that can generate revenue and cash flow before the launch of a new drug.